These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 26044889)

  • 1. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
    Lauffenburger JC; Rhoney DH; Farley JF; Gehi AK; Fang G
    Pharmacotherapy; 2015 Jun; 35(6):560-8. PubMed ID: 26044889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
    Sherid M; Sifuentes H; Sulaiman S; Samo S; Husein H; Tupper R; Spurr C; Sridhar S
    Korean J Gastroenterol; 2015 Apr; 65(4):205-14. PubMed ID: 25896154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
    Hernandez I; Zhang Y; Brooks MM; Chin PK; Saba S
    Stroke; 2017 Jan; 48(1):159-166. PubMed ID: 27909200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Gislason GH; Lip GY; Fosbøl EL; Hansen ML; Lamberts M; Bonde AN; Torp-Pedersen C; Olesen JB
    Europace; 2015 Aug; 17(8):1215-22. PubMed ID: 25995392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
    Flack KF; Desai J; Kolb JM; Chatterjee P; Wallentin LC; Ezekowitz M; Yusuf S; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Clin Gastroenterol Hepatol; 2017 May; 15(5):682-690. PubMed ID: 27765728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
    Abe J; Umetsu R; Kato Y; Ueda N; Nakayama Y; Suzuki Y; Suzuki T; Nagasawa H; Kinosada Y; Nakamura M
    Int J Med Sci; 2015; 12(4):312-21. PubMed ID: 25897292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA; Chee KH; Lo YL
    Int J Clin Pharm; 2016 Oct; 38(5):1182-90. PubMed ID: 27450507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    Am J Cardiol; 2015 Apr; 115(8):1095-101. PubMed ID: 25724781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.